Sulfoximine-substituted trifluoromethylpyrimidine analogs as inhibitors of proline-rich tyrosine kinase 2 (PYK2) show reduced hERG activityWALKER, Daniel P; ZAWISTOSKI, Michael P; MISTRY, Anil et al.Bioorganic & medicinal chemistry letters (Print). 2009, Vol 19, Num 12, pp 3253-3258, issn 0960-894X, 6 p.Article

Trifluoromethylpyrimidine-based inhibitors of proline-rich tyrosine kinase 2 (PYK2) : Structure-activity relationships and strategies for the elimination of reactive metabolite formationWALKER, Daniel P; BI, F. Christopher; MCGLYNN, Molly A et al.Bioorganic & medicinal chemistry letters (Print). 2008, Vol 18, Num 23, pp 6071-6077, issn 0960-894X, 7 p.Article

Potent small molecule CCR1 antagonistsKATH, John C; BRISSETTE, William H; MARTIN, William H et al.Bioorganic & medicinal chemistry letters (Print). 2004, Vol 14, Num 9, pp 2169-2173, issn 0960-894X, 5 p.Article

Piperazinyl CCR1 antagonists : optimization of human liver microsome stabilityBROWN, Matthew F; BAHNCK, Kevin B; GUZMAN-MARTINEZ, Aikomari et al.Bioorganic & medicinal chemistry letters (Print). 2007, Vol 17, Num 11, pp 3109-3112, issn 0960-894X, 4 p.Article

Novel CCR1 antagonists with improved metabolic stabilityBROWN, Matthew F; AVERY, Mike; LIRA, Paul D et al.Bioorganic & medicinal chemistry letters (Print). 2004, Vol 14, Num 9, pp 2175-2179, issn 0960-894X, 5 p.Article